BTPmd
Dear Fellow Investors,
Yet another potential big 10-bagger winner that some people are saying could be one of the biggest breakthroughs in years for Diabetes. GVEST Inc., has just signed a letter of intent with a public shell company FROI to sell Sucanon, also known as Diab II ,one of only three drugs, Avandia (Glaxo), Actos (Takeda), and Sucanon, approved anywhere in the world, belonging to a new category of drugs called "insulin sensitizers". FROI has jumped the shark by signing a letter of intent to acquire a drug already approved in two Latin American countries, and FROI not only acquires the drug, but also get distribution and sales through Merck, Costco, and Walmart of Latin America; in the asset purchase consisting of yet an undisclosed amount of cash and stock.
Important facts investors need to know about Sucanon:
Sucanon is one of only three drugs approved anywhere in the world, belonging to a new category of drugs called "insulin sensitizers".
Sucanon has received regulatory approval in Mexico. Mexico is the tenth largest pharmaceutical market and one of the largest diabetic markets in the world.
Sucanon is now sold in more than 600 stores nationally in Mexico including outlets of at least six drugstore chains.
Sucanon has received regulatory Rx approval in Peru, and has a signed agreement for distribution in Ecuador and Costa Rica.
Sucanon is available in Costco Mexico and Wal-Mart Mexico. Gvest Inc. through its Mexican subsidiary Pharmaroth Latin America S.A. de C.V. has an agreement with Merck S.A. de C.V. in Mexico and Latin America for the distribution of Sucanon.
For more Sucanon information please visit: http://www.sucanonhealth.com
Worldwide Market for "Insulin Sensitizers" $5.6 billion a year !
1. Avandia sales for 2009 totaled $1.2 billion worldwide - Glaxo (GSX - $37.29)
2. Actos sales $4.4 billion for the year ended March 2009. - Takeda (TKPHY - $21.35)
3. Sucanon worldwide sales for 2009 -unknown - Fero Industries (FROI - $0.23)
This landmark acquisition by Fero Industries, (FROI : OTCBB), of the intellectual property, patents, and other rights related to the production, marketing and distribution of Sucanon from GVEST, is sure to place FROI squarely on the radar screens of Wall Street Traders, Investors, and Pharmaceutical Venture Capital firms alike. Savvy investors will see the opportunity of owning one of only three approved drugs in a $5.6 billion dollar "insulin sensitizer" international market. This market is expected to grow by epidemic proportions as up to 80% of the U.S. population could be diagnosed with diabetes by 2018 according to an April 30th BARRON'S article: http://www.bloomberg.com/apps/news?pid=20601124&sid=ad044bJ3k3co
Do your research now while FROI is still trading under $0.30 per share. If Sucanon can capture just one percent of the world market for "insulin sensitizers" the stock could easily be over a $1.00 stock. Short term we believe FROI has the ability to hit the $0.75 to $0.85 range and long term could see $2.00 to $3.00 per share once the investing public sees the value of this transaction. Fellow investors FROI could truly be one of those rare ground floor big 10-bagger winners you have been waiting for.
Don't wait, you can start your research here: http://finance.yahoo.com/q?s=FROI.OB
Be sure to check out our site for updates here: http://beyondthepenny.com
No comments:
Post a Comment